Historical AI Consensus

This page preserves the research and market snapshot packaged for this batch. It is not updated with later prices or revised advisor outputs.

Symbol: SYK.NYSE
Batch: 7
Published: September 20, 2026
AI Advisors: 14

Historical AI Consensus Investment Thesis

Stryker (SYK) Stock Forecast and AI Rating

Deep analysis published Sep 21 2026Original pricing snapshot Sep 18 2026

Publisher

Russlan Ramdowar

12 min read

Published 1-Year and 5-Year Forecast Outlook

Forecast targets and rating

Published batch rating

BUY

Calculated from the frozen synthesized path using the same return, horizon, volatility and dividend rules as individual opinions.

2027

1-Year

STRONG BUY

$316

+14.9%+15.7% incl. dividends

2031

5-Year

BUY

$513

+86.6%+93.3% incl. dividends

Published batch insight

Operational Recovery and Outpatient Robotics Create Mispriced Surgical Cash Flows

There is high consensus that non-cyclical procedural demand and installed robotic ecosystems anchor long-term compounding, while sharp divergence persists over near-term peripheral vascular supply bottlenecks. Valuation multiple recovery remains conditional on operational recovery and hospital capital budgeting flexibility.

Deep Forecast Analysis by iPulse AI Engine

This analysis preserves the original published batch. Audit published forecasts in full transparency

Universal Investor (Polymath), Ray Dalio (Strategist), J.P. Morgan (Titan), Warren Buffett (Value Purist), Sherlock Holmes (Whistleblower), Michael Burry (Vulture), Superintelligence (Anthropologist), Elon Musk (Visionary), Machiavelli (Insider). Some archetypes run in multiple modes, resulting in 14 advisors total.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Full published thesis

Executive Summary

If you invested $10,000 in Stryker at the forecast anchor (2026-09-18): $19,326 in five years versus $13,892 for S&P 500 benchmark.

Stryker · Synthesized ConsensusS&P 500 benchmark

* Return is calculated incl. 0.7% net dividend yield for Stryker.

Figure: Five-year synthesized consensus value path for Stryker compared with S&P 500 benchmark. The path uses the synthesizer’s normalized opinion weights.

20-quarter synthesized forecastPrice targets, quarterly returns and the reasoning behind each stepView table

Frozen forecast from 18 Sept 2026. Prices in USD; returns exclude dividends. Each quarter is compounded from the previous quarter.

Anchor: 275.12 USD1-year price return: +14.87%5-year price return: +86.63%

Swipe the table horizontally to read every column.

Twenty quarterly synthesized price forecasts in USD, with returns and rationale
Quarter	Target (USD)	Quarter return	Total return	Forecast rationale
Q4 2026	279.60	+1.63%	+1.63%	Third-quarter results reflect lingering peripheral vascular backorders and hospital equipment budget caution, but resilient elective procedural volumes and initial conversion of capital backorders cushion equity downside from oversold valuation levels.
Q1 2027	292.07	+4.46%	+6.16%	Fourth-quarter reporting confirms manufacturing throughput stabilization across acquired vascular facilities, while full-year guidance frames realistic targets. Reduced operational downside uncertainty prompts institutional short covering and initiates measured multiple stabilization.
Q2 2027	305.47	+4.59%	+11.03%	Commercial scaling of handheld robotic platforms in ambulatory surgery centers unlocks outpatient procedure growth. Favorable implant pull-through and recovering vascular shipments expand adjusted operating margins, supporting solid upward earnings revisions.
Q3 2027	316.04	+3.46%	+14.87%	Second-quarter joint arthroplasty demand shows solid unit volume expansion across North America and Europe. High-margin consumable utilization offsets seasonal summer scheduling moderation, keeping quarterly cash generation resilient.
Q4 2027	329.30	+4.20%	+19.69%	Year-end hospital capital budget releases drive robotic console deliveries and digital operating suite installations. Strong operational cash flow accelerates post-acquisition balance sheet deleveraging, reinforcing investor confidence in earnings durability.
Q1 2028	339.60	+3.13%	+23.44%	Full-year financial reporting confirms expanding operating margins and free cash flow exceeding five billion dollars. A modest dividend increase validates capital discipline, sustaining positive momentum despite restrictive benchmark interest rates.
Q2 2028	352.49	+3.79%	+28.12%	Expanded clinical indications for robotic shoulder and extremity procedures broaden the commercial addressable market. High-margin reconstructive consumables drive divisional operating leverage, insulating cash flow from persistent hospital procurement scrutiny.
Q3 2028	359.40	+1.96%	+30.63%	Hospital financing costs and procurement reviews temporarily moderate large-scale equipment purchases during seasonal lulls. Inelastic joint and trauma consumable volumes cushion operating income, keeping quarterly price action relatively stable.
Q4 2028	373.95	+4.05%	+35.92%	Delayed surgical equipment orders convert ahead of fiscal year-end, while high fourth-quarter procedure throughput boosts consumable replenishment. Working capital discipline generates exceptional cash conversion, supporting steady share appreciation.
Q1 2029	385.02	+2.96%	+39.95%	Annual financial disclosures highlight high-single-digit organic revenue growth and sustained margin discipline. Prudent balance-sheet management reduces net debt, providing ample strategic flexibility to fund selective tuck-in acquisitions.
Q2 2029	397.97	+3.36%	+44.65%	European and Asian adoption of robotic-assisted joint replacement accelerates, alleviating waiting lists and expanding international revenues. Incremental software licensing and consumable revenues outpace rising regulatory compliance costs.
Q3 2029	408.50	+2.65%	+48.48%	Demographic tailwinds provide steady baseline volume growth across hips and knees. Moderate competitive pricing pressure from rival robotic platforms is offset by surgeon loyalty and sticky hospital workflow integration.
Q4 2029	423.68	+3.72%	+54.00%	Year-end capital commitments for integrated digital surgical suites combine with peak deductible-driven procedure volumes. Free cash flow generation reaches new highs, encouraging institutional allocation toward defensive medtech compounders.
Q1 2030	435.69	+2.83%	+58.36%	Full-year reporting establishes a mature, cash-backed earnings foundation. Structural operating productivity offsets ongoing medical alloy and tariff inflation, enabling steady earnings-led appreciation while terminal valuation multiples remain disciplined.
Q2 2030	449.19	+3.10%	+63.27%	Outpatient surgical centers achieve mature utilization, with proprietary implants commanding leading share in decentralized facilities. Rapid inventory velocity and disciplined commercial overhead sustain robust quarterly operating earnings.
Q3 2030	460.11	+2.43%	+67.24%	Late-cycle macroeconomic headwinds and public healthcare budgetary reviews cap realized implant price increases. However, non-discretionary procedural necessity protects unit demand, keeping operating cash flow generation stable.
Q4 2030	475.49	+3.34%	+72.83%	Strong fourth-quarter surgical caseloads and replacement cycles for aging capital systems drive solid year-end shipments. Management authorizes expanded capital returns, cementing shareholder confidence across institutional allocators.
Q1 2031	487.33	+2.49%	+77.13%	Annual results confirm multi-year operating margin expansion toward cycle targets. Compounding free cash flow and a substantially fortified balance sheet position the business for sustainable long-term value creation.
Q2 2031	501.85	+2.98%	+82.41%	Next-generation surgical planning software updates defend robotic utilization across global hospital accounts. High-margin consumable attachment preserves operating profitability despite aggressive bidding from modular robotic competitors.
Q3 2031	513.47	+2.31%	+86.63%	The forecast horizon closes with robust operational execution and normalized cash flows validating franchise resilience. Steady organic volume growth and disciplined capital allocation deliver durable risk-adjusted equity compounding.

The base-case economic thesis identifies a transient valuation disconnect where market participants have priced temporary manufacturing dislocations and cyber-remediation expenses as permanent structural impairment. Underlying revenue durability is anchored by an installed base exceeding three thousand robotic systems, converting upfront capital placements into decade-long, high-margin implant consumable annuities that compound through demographic necessity. Valuation remains highly sensitive to hospital capital expenditure financing costs under five-percent sovereign yields and management's operational execution on vascular supply recovery. The primary counterargument contends that prolonged factory bottlenecks have permanently ceded thrombectomy share to competitors while hospital capex freezes cap console placements.

Key insights

Razor-and-blade procedural mechanics generate over seventy-five percent of revenues from recurring implants, completely insulating operating cash flows from industrial cyclicality.
Ambulatory surgical center expansion via handheld robotics unlocks high-velocity outpatient procedure volume, delivering superior operating leverage and distribution economics.
Trailing free cash flow of $4.70 billion comfortably funds programmatic debt deleveraging, ensuring strategic resilience despite restrictive global monetary conditions.

Deep Dive

Prevailing market consensus treats the business as a stumbling compounder burdened by compounding operational dysfunction, pointing to delayed vascular supply fixes, softer summer hip volumes, and high hospital borrowing hurdles. Media commentary and sell-side downgrades fixate on near-term multiple compression, assuming that elevated interest rates permanently cap institutional capital budgets and compress organic revenue growth.

Paywalled preview begins: Deep Dive

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Alpha Gap & Repricing Catalysts

Where the published AI consensus diverged from the market narrative

Market narrative

Alpha gap

The crowd underestimates equity value by misdiagnosing transitory manufacturing bottlenecks as structural franchise decay, pricing shares at a rare cyclical discount. The analytical edge lies in recognizing that over three-quarters of revenue derives from non-cyclical procedural consumables and captive implants rather than discretionary capital equipment. While the market extrapolates delayed shipments into permanent share loss, installed robotic moats and outpatient procedural migration ensure that cash flows quickly reaccelerate once manufacturing throughput normalizes.

Repricing catalyst

Consecutive quarterly earnings prints confirming complete manufacturing restoration across peripheral vascular lines and sustained organic growth above eight percent will decisively close the valuation gap. Institutional repricing will accelerate as capital equipment backorders convert into billed shipments and outpatient robotic placements demonstrate expanding market share throughout 2027, forcing sell-side analysts to lift forward earnings estimates.

Published consensus context

Macro regime alignment

The prevailing monetary regime of elevated policy rates and five-percent Treasury yields is a valuation headwind that tightens hospital capital budgets and raises financing hurdles for large equipment purchases. However, biological necessity renders joint replacement demand almost entirely price-inelastic, enabling strong operating cash flows to easily outpace broader macroeconomic stagflation.

Published consensus context

Advisor disagreement

The decisive analytical tension pits views assuming rapid mean-reversion in valuation multiples against those modeling a permanently lower multiple floor. The optimistic camp assumes that peripheral vascular bottlenecks will resolve cleanly by year-end, restoring high-single-digit organic growth and expanding operating margins past twenty-five percent. Conversely, skeptics argue that prolonged stockouts have permanently ceded procedural volume to competitors and that management guidance credibility has suffered. Resolving this disagreement requires observing third- and fourth-quarter vascular organic sales trends and verifying whether hospital capital equipment order backlogs convert cleanly into billed shipments.

Published scenario analysis

Base-case forces, risks, and opportunities

Top drivers and tailwinds

Mako surgical ecosystem procedural lock-in: An installed base exceeding three thousand robotic units performs over half of global robotic knee procedures, locking hospital orthopaedic suites into proprietary implants. High surgeon switching costs secure predictable high-margin consumable annuities, insulating cash flows from macro volatility and driving high-single-digit revenue expansion. Expected impact: +31%.
Demographic surge in non-discretionary arthroplasty: Accelerating global aging ensures an inelastic, non-cyclical wave of joint replacement, trauma, and extremity surgeries that patients cannot postpone indefinitely. This demographic expansion guarantees resilient procedural volume growth, underwriting predictable top-line revenue gains and providing durable cash flow protection across fluctuating economic cycles. Expected impact: +22%.
Ambulatory surgical center procedural migration: The rapid migration of orthopaedic procedures into outpatient surgical centers favors specialized, compact equipment. Commercial rollout of handheld robotics and turnkey surgical buildouts captures high-velocity outpatient accounts, lowering distribution friction, expanding operating margins, and driving superior capital turnover. Expected impact: +20%.
Peripheral vascular supply and synergy restoration: Resolving manufacturing and cleanroom bottlenecks within acquired peripheral vascular facilities eliminates an estimated eighty basis points of organic drag. As production lines normalize, high-margin mechanical thrombectomy catheters ramp to scale, restoring operating leverage and accelerating consolidated earnings per share compounding. Expected impact: +18%.

Top frictions and headwinds

Hospital capital expenditure financing squeeze: Elevated benchmark borrowing yields compress non-profit hospital operating margins and debt-financing capacity. Healthcare procurement committees are extending replacement cycles and scrutinizing major capital equipment purchases, dampening upfront robotic hardware shipments and lengthening sales cycles across institutional accounts. Expected impact: -14%.
Reimbursement containment and procurement caps: Public payers and commercial insurers continue tightening orthopaedic fee schedules, emphasizing bundled episode payments and site-neutral pricing. These regulatory caps restrict gross pricing flexibility on commodity implants, forcing ongoing manufacturing cost-reduction efforts to defend corporate operating margins. Expected impact: -11%.
Supply chain tariffs and input inflation: Replacement Section 301 tariffs, trade frictions, and raw material inflation across medical-grade titanium and microelectronics elevate manufacturing costs. Multi-year fixed hospital procurement contracts prevent immediate wholesale price adjustments, creating persistent gross margin friction that trims operating profitability. Expected impact: -9%.
Post-acquisition debt service capital absorption: Substantial debt incurred to fund the nearly five-billion-dollar Inari Medical acquisition elevates annual interest commitments under higher refinancing rates. Slower balance sheet deleveraging absorbs discretionary operational cash flows, temporarily restricting share repurchases and moderating per-share earnings compounding. Expected impact: -8%.

Tail risks

Prolonged vascular regulatory manufacturing sanctions: Persistent quality-control deficiencies or cleanroom yield failures at acquired peripheral vascular facilities could trigger an FDA warning letter or consent decree. Mandated facility halts and remediation expenses would forfeit high-margin procedural revenues, prompt material goodwill impairments, and cause lasting institutional valuation multiple de-rating. Probability: +24%. Expected impact: -26%.
Systemic clinical network cyberattack disruption: A sophisticated state-sponsored cyber offensive breaching operational networks or cloud-connected surgical telemetry could force mandatory device shutdowns across hospital operating rooms. Beyond immediate remediation and litigation expenses, clinical cancellations would impair customer trust and depress operating income across the device sector. Probability: +19%. Expected impact: -28%.

Tail opportunities

Accelerated outpatient robotics reimbursement parity: A decisive regulatory overhaul granting full procedural reimbursement parity and incentive bonuses for robotic-assisted joint replacements in ambulatory surgery centers would trigger rapid outpatient hardware adoption. Capturing dominant market share across expanding surgical centers would accelerate consumable implant pull-through and significantly increase earnings growth above current forecasts. Probability: +32%. Expected impact: +24%.
Autonomous soft-tissue robotic clearance: Securing accelerated FDA clearance for next-generation autonomous soft-tissue balancing algorithms embedded in robotic platforms would expand addressable surgical applications into spine and soft-tissue reconstruction. Faster operative throughput and reduced revision rates would spur an aggressive hospital replacement cycle, driving premium recurring software revenues. Probability: +26%. Expected impact: +28%.

What to monitor

Thesis watchpoints

-- Confirmation requires organic revenue growth sustaining at or above eight percent with peripheral vascular backorders cleared across the next two quarterly reports.

Key insights

Deterioration appears if trailing twelve-month free-cash-flow margin drops below eighteen percent alongside flat joint-replacement procedural volumes through mid-2027.
Reassessment is triggered by any FDA regulatory warning letter regarding vascular manufacturing facilities or consecutive quarters of contracting robotic placements.

Company Financial Analysis

Stryker Earnings and Financials Analysis by AI

Financial figures available as of Sep 20, 2026. Only filings and source records available by this analysis date are included.

Earnings and financials

AI Review

Stryker's financial performance highlights the remarkable resilience of its core medical business. Full-year 2025 revenue grew by 11.2% to $25.1 billion, and momentum continued with trailing revenue reaching $25.8 billion through mid-2026. While an early-2026 cyber incident and factory delays in peripheral vascular products caused temporary quarterly hiccups, underlying procedure demand rebounded quickly. Crucially, headline accounting figures obscure superior cash generation. Trailing free cash flow reached an impressive $4.70 billion, easily surpassing reported net income. Because surgical operations require constant replenishments of implants and single-use tools, revenue converts reliably into cash even during broader economic slowdowns.

Revenue, earnings, and cash flow

The table compares up to five fiscal years of revenue, net income, and free cash flow available to this analysis.

Revenue, net income, and free cash flow history
Fiscal year	Revenue	Net income	Free cash flow
2025	USD 25.1B	USD 3.2B	USD 4.3B
2024	USD 22.6B	USD 3B	USD 3.5B
2023	USD 20.5B	USD 3.2B	USD 3.1B
2022	USD 18.4B	USD 2.4B	USD 2B
2021	USD 17.1B	USD 2B	USD 2.7B

Valuation context: historical P/E

The table compares up to five fiscal years of point-in-time valuation evidence available to this analysis.

Historical price-to-earnings ratios
Fiscal year	P/E	Earnings basis	Currency basis	Ticker / reporting
2025	41.8x	TTM	Native	USD / USD
2024	46.4x	TTM	Native	USD / USD
2023	36.3x	TTM	Native	USD / USD
2022	39.6x	Annual	Native	USD / USD
2021	51.3x	Annual	Native	USD / USD

P/E uses historical market capitalization and earnings known at each period. Cross-currency observations are normalized to USD using point-in-time FX rates.

Profitability and margins

AI Review

Stryker demonstrates strong structural pricing power and operating efficiency across its operations. Gross margins widened to 64.0% in 2025, driven by premium pricing for specialized robotic implants and an advantageous mix of surgical instruments. While operating margins dipped temporarily to 19.5% in 2025 due to acquisition integration costs and supply chain friction, adjusted operating margins quickly rebounded above 22% on a trailing basis. As temporary factory bottlenecks clear and outpatient surgical centers expand, operating leverage will continue driving profits faster than sales.

The table compares up to five fiscal years of operating income and reported profitability margins.

Operating income and margin history
Fiscal year	Operating income	Operating margin	Net margin
2025	USD 4.9B	19.5%	12.9%
2024	USD 5.1B	22.4%	13.2%
2023	USD 4.3B	20.9%	15.4%
2022	USD 3.7B	20.2%	12.8%
2021	USD 3.8B	22.0%	11.7%

Balance sheet and leverage

AI Review

The balance sheet reflects substantial financial strength built to withstand high interest rates. Stockholders' equity stood at $22.4 billion at the end of 2025, while debt-to-equity remained comfortable at 0.73 despite borrowing to finance the $4.9 billion Inari acquisition. With annual interest coverage well above eight times operating profit and a current ratio near 1.9, debt obligations are fully manageable. The company's massive annual free cash flow allows steady, orderly debt reduction, preserving complete borrowing flexibility for future technology investments without risking financial distress.

The table compares up to five fiscal years of debt, liquidity, net cash or debt, and current-ratio evidence.

Balance sheet leverage and liquidity history
Fiscal year	Total debt	Cash + short-term investments	Net cash / (debt)	Current ratio
2025	USD 16.4B	USD 4.1B	USD 12.3B net debt	1.89x
2024	USD 1.4B	USD 4.4B	USD 9.9B net debt	1.95x
2023	USD 13.5B	USD 3.1B	USD 10.5B net debt	1.58x
2022	USD 13.5B	USD 1.9B	USD 11.7B net debt	1.63x
2021	USD 12.5B	USD 3B	USD 9.5B net debt	2.20x

Net debt below zero is displayed as net cash. Current ratio is current assets divided by current liabilities.

Capex and investment intensity

AI Review

Management follows a disciplined, asset-light investment strategy that avoids sinking unnecessary money into heavy real estate or excess factories. Capital expenditures remain tightly controlled at roughly 3.0% of annual revenue, freeing up cash for higher-return opportunities. Instead of overbuilding physical facilities, the company reinvests heavily through its income statement, channeling $1.58 billion into research and development in 2025. This targeted spending funds proprietary robotic software and next-generation surgical tools, while operating cash flow self-funds strategic acquisitions like Inari Medical without overburdening core finances.

The table compares up to five fiscal years of capital expenditure and research-and-development investment.

Capital expenditure and research and development history
Fiscal year	Capital expenditure	R&D spend
2025	USD 761M	USD 1.6B
2024	USD 755M	USD 1.4B
2023	USD 575M	USD 1.3B
2022	USD 588M	USD 1.2B
2021	USD 525M	USD 1.1B

Immutable published data

Averaged consensus horizons

The table preserves this publication's original rating, return, and advisor-agreement measurements by forecast horizon.

Horizon	Rating	Score incl. dividends	Compounded return incl. dividends	Direction agreement	Snapshot
1Y	BUY	297	+15.6%	Not available	ORIGINAL
5Y	BUY	270	+95.3%	Not available	ORIGINAL

Averaged consensus scenarios

The table outlines the frozen bear, consensus, and bull price scenarios for each published forecast period.

Period	Date	Bear case	Consensus	Bull case	AI Advisors
+3M	December 18, 2026	261.36	282.59	288.88	14
+6M	March 18, 2027	279.66	293.4	306.15	14
+9M	June 18, 2027	296.44	306.6	321.46	14
+1Y	September 18, 2027	303.61	316.02	334.32	14
+15M	December 18, 2027	315.75	329.36	351.04	14
+18M	March 18, 2028	318.91	339.33	372.1	14
+21M	June 18, 2028	328.48	352.95	386.98	14
+2Y	September 18, 2028	336.56	361.13	406.33	14
+27M	December 18, 2028	350.02	375.87	422.58	14
+30M	March 18, 2029	358.9	386.99	443.71	14
+33M	June 18, 2029	369.67	400.93	461.46	14
+3Y	September 18, 2029	377.06	411.63	475.31	14
+39M	December 18, 2029	388.38	427.26	494.32	14
+42M	March 18, 2030	392.26	439.34	519.03	14
+45M	June 18, 2030	404.03	453.86	534.6	14
+4Y	September 18, 2030	412.11	464.75	555.99	14
+51M	December 18, 2030	424.47	480.34	572.67	14
+54M	March 18, 2031	428.72	492.6	595.58	14
+57M	June 18, 2031	437.29	507.51	613.44	14
+5Y	September 18, 2031	446.04	519.7	631.85	14

Frozen comparison context

SPDR S&P 500 ETF Trust forecast context

The benchmark definition and forecast path are frozen with this publication so future benchmark changes do not rewrite the historical comparison.

Benchmark snapshot: 761.69 on September 18, 2026

Period	Date	Bear case	Consensus	Bull case
+3M	December 18, 2026	723.6055	750.2647	769.3069
+6M	March 18, 2027	701.8973	736.44	784.693
+9M	June 18, 2027	695.1	743.3975	808.2338
+1Y	September 18, 2027	681.198	755.1476	816.3162
+15M	December 18, 2027	688.01	776.2182	840.8057
+18M	March 18, 2028	701.7702	787.1259	857.6218
+21M	June 18, 2028	722.8233	802.8344	883.3504
+2Y	September 18, 2028	730.0515	812.0465	892.1839
+27M	December 18, 2028	751.9531	839.1839	927.8713
+30M	March 18, 2029	766.9921	850.5008	946.4287
+33M	June 18, 2029	782.332	872.3935	965.3573
+3Y	September 18, 2029	790.1553	885.5111	975.0109
+39M	December 18, 2029	805.9584	909.5618	1,004.2612
+42M	March 18, 2030	822.0776	916.132	1,024.3464
+45M	June 18, 2030	830.2984	936.5109	1,055.0768
+4Y	September 18, 2030	830.2984	947.3438	1,065.6276
+51M	December 18, 2030	855.2073	969.5876	1,097.5964
+54M	March 18, 2031	872.3114	979.9863	1,119.5483
+57M	June 18, 2031	889.7577	999.6043	1,141.9393
+5Y	September 18, 2031	898.6553	1,011.7644	1,153.3587

Behind the synthesis

How each opinion shapes the consensus

14 opinions · 100% allocated

The independently supported consensus establishes that core reconstructive procedural demand is non-cyclical, sustained by demographic aging and an installed base of over three thousand robotic systems that command high-margin consumable implant pull-through. However, analytical divergence emerges regarding whether recent peripheral vascular manufacturing bottlenecks and summer orthopaedic softness represent brief operational friction or structural market share defection. Heaviest weights are allocated to reports that independently audit SEC filings, separate nonrecurring tariff refunds from structural margin gains, and account for management credibility headwinds following delayed remediation disclosures. Reports that mechanically assume an immediate re-rating to peak historical multiples are downweighted, as elevated sovereign yields and tight hospital capital expenditure budgets impose ongoing valuation friction.

AI RESEARCHER

Universal Investor AI

The Polymath

GPT-6 Astra

Weight14.7/100

Offering exceptional evidentiary rigor, this report cross-checks SEC filings, highlights working-capital distortions in trailing cash conversion, and identifies permanent procedural share loss during supply stockouts. Its grounded cash-flow valuation and disciplined multiple assumptions justify a top-tier weight.

AI RESEARCHER

Universal Investor AI

The Polymath

The Anthropologist

Gemini 3.8 Flash

Weight3.9/100

This submission outlines demographic volume drivers well, but duplicates the preceding report's framework and qualitative reasoning without providing fresh data verification, justifying a reduced standalone allocation.

Skip to references

Research Provenance

References & Context

This Stryker consensus analysis combines structured market evidence with independent AI-agent forecasts. External references below are limited to sources recorded by the researcher agents for this forecast batch.

Primary analysis inputs

iPulse AI Multi-Agent Forecasts — independent analyst personas, model outputs, and consensus synthesis.
iPulse AI Global Events Context — macroeconomic, geopolitical, regulatory, and industry-event context.
Structured market history — prices, distributions, volatility, identifiers, and listing metadata.
Company earnings and financial statements — revenue, profitability, balance-sheet, cash-flow, and investment trends.
Researcher web evidence — public sources consulted to challenge and contextualize the forecast thesis.

Independent AI Advisor panel

AI Advisors: 14
AI Researchers: 11
AI Thinkers: 3

Sources retained from AI Researcher searches

Asset-specific · Researcher web

Showing the top 15 of 132 deduplicated sources retained for this batch.

018-Ksec.gov
02syk-20260630sec.gov
03www.sec.govsec.gov
04Resilient Stryker stock holds after Q2 2026 earnings beat and fresh EPS guidancead-hoc-news.de
05Stryker stock heads into the open after a 1.95% dropad-hoc-news.de
06Stryker stock heads into the open after a 3.6% slidead-hoc-news.de
07Stryker stock holds above $330 as investors weigh FY 2026 guidancead-hoc-news.de
08Medical Technology Stocks: Innovation Endures as Valuations Resetbernstein.com
09[SYK Q2 2026 Earnings Call] Stryker Organic Sales Rise 9%, EPS Jumps 17.9%; Narrows 2026 Guidance on Strong Capital Backlog — BigGo Financefinance.biggo.com
10Stryker Corp (SYK) (Q2 2026) Earnings Call Highlights: Strong 9% Organic Growth and Raised ...finance.yahoo.com
11STRYKER CORP. R (SYK.MU) Q1 FY2026 earnings call transcriptfinance.yahoo.com
12Stryker Corporation (SYK) Stock Price, News, Quote & History - Yahoo Financefinance.yahoo.com
13Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSSglobenewswire.com
14Medical device stocks tumble after HCA flags weak surgical volumes By Investing.cominvesting.com
15Stryker at wells fargo healthcare conference: growth tested by supply By Investing.cominvesting.com

And 117 more sources were used and retained in the batch inventory.

Context retained with this Consensus

The same public-safe market, global-event, and fundamental context supplied to the AI Advisor panel.

Global context snapshot

2025 Full-Year Global Market and World-Events Context

Download Archived Snapshot

Coverage 2025-01-01 to 2025-12-31 · Knowledge cutoff 2025-12-31

This full-year context package covers the principal geopolitical, economic, monetary-policy, technology, trade, energy, and institutional developments that shaped global markets during 2025. It gives the forecasting model a chronological account of major world events together with their likely transmission into growth, inflation, interest rates, supply chains, commodities, currencies, public markets, and sector-level investment conditions.

The package also includes monthly and quarterly macroeconomic and cross-asset reference tables spanning US and international growth, central-bank policy, sovereign yields, major equity indices, foreign exchange, energy, industrial and precious metals, and digital assets. Quarterly and full-year high-impact summaries are integrated; monthly quantitative series remain working values pending final audit, and that qualification is part of the preserved context.

Top 3 market shifts from 2025 Full-Year Global Market and World-Events Context
Top 3 Market Shifts From File	Date	Status
DeepSeek shock and AI economics reset	2025-01-27	OPEN ENDED TREND
US tariff regime escalation and trade-system rupture	2025-02-01	ACTIVE POLICY REGIME
Federal Reserve easing cycle after a prolonged hold	2025-09-17	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics US Bureau of Economic Analysis US Treasury US Energy Information Administration Reuters World Associated Press World News BBC World

And more sources from the retained context package.

2026 Year-to-Date Global Market and World-Events Context Through September 20

Download Archived Snapshot

Coverage 2026-01-01 to 2026-09-20 · Knowledge cutoff 2026-09-20

January 1-September 20, 2026: monetary tightening, energy security, trade restrictions, AI financing and divergent growth; five leading market themes.

Fed raised rates to 3.75%-4.00%; ECB hike is in force and BOJ increase starts September 24. Markets through September 18, bitcoin through September 19.

Top 3 market shifts from 2026 Year-to-Date Global Market and World-Events Context Through September 20
Top 3 Market Shifts From File	Date	Status
Renewed monetary tightening amid persistent inflation	2026-01-30	ACTIVE POLICY REGIME
Iran/Hormuz conflict and wider energy-security disruption	2026-02-28	ONGOING
Tariff legal reset and strategic supply restrictions	2026-02-20	ACTIVE POLICY REGIME

Representative Sources of the Context File

Federal Reserve US Bureau of Labor Statistics European Central Bank International Monetary Fund Reuters World Associated Press World News

And more sources from the retained context package.

Fundamental context

Income statement

9 fields

depreciationAndAmortization · ebit · ebitda · grossProfit · +5 more fields

Balance sheet

12 fields

cash · commonStockSharesOutstanding · longTermDebt · netDebt · +8 more fields

Cash flow

5 fields

capitalExpenditures · dividendsPaid · freeCashFlow · salePurchaseOfStock · +1 more field

annual: 2014-12-31–2025-12-31, 12 periods; quarterly: 2023-09-30–2026-06-30, 12 periods

Currencies cited: USD (quote USD; primary reporting USD; converted/valuation USD).

End of the paywalled preview

The excerpt from Deep Dive to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Individual AI Advisor reports
- Separate investment theses, scenarios, factors, risks and opportunities
- Quarterly forecast events and supporting citations
- Published advisor configuration snapshots
Interactive research tools
- Zoomable forecast and benchmark comparisons
- Currency and dividend assumptions
- Additional datasets and eligible historical research

Explore complete public research examples

These public assets show the complete AI Consensus research. Their findings concern those assets, not this report.